Merck KGaAs ETR:MRK Fundamentals Look Pretty Strong: Could The Market Be Wrong About the Stock?

MRK Merck & Co., Inc. has recently received FDA approval to expand the use of its top-selling drug Keytruda. This news has led to positive expectations for the company's future performance. Additionally, Merck's NUMELVI has received EU backing as the first JAK inhibitor for young dogs, showcasing the company's commitment to innovation in the pharmaceutical industry. With strong fundamentals and promising developments, could the market be underestimating the potential of MRK stock?